Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 16:05 ET
|
Bolt Biotherapeutics, Inc.
– BDC-1001 monotherapy and combination dose-escalation portion of the trial in HER2-expressing solid tumors on track to complete this year– New portfolio prioritization and capital allocation strategy...
Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022
May 27, 2022 08:00 ET
|
Bolt Biotherapeutics, Inc.
- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present - REDWOOD CITY, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq:...
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
May 12, 2022 16:05 ET
|
Bolt Biotherapeutics, Inc.
– BDC-1001 monotherapy and OPDIVO® combination trials progressing toward data readouts in second half of 2022 – Cash balance of $246.8 million expected to fund key milestones and operations into...
Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference
April 07, 2022 08:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that...
Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights
March 30, 2022 16:05 ET
|
Bolt Biotherapeutics, Inc.
BDC-1001 for the treatment of patients with HER2-expressing solid tumors on track for recommended Phase 2 dose identification later in 2022; BDC-1001 combination study arm with OPDIVO® (nivolumab)...
Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022
March 08, 2022 16:30 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that...
Bolt Biotherapeutics to Participate in Upcoming February Conferences
February 02, 2022 08:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the...
Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors
January 06, 2022 08:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that...
Bolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directors
December 16, 2021 08:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the...
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021
December 06, 2021 06:00 ET
|
Bolt Biotherapeutics, Inc.
Company to continue monotherapy dose-escalation and evaluate weekly dose regimen Combination dose-escalation study of BDC-1001 with Opdivo® on target to initiate by year end 2021 Live conference...